RTN-001 is a first-in-class, potent, selective, second-generation PDE5 inhibitor. While first generation PDE5 inhibitors failed to deliver on their full potential, PDE5 remains a key therapeutic target for the treatment of hypertension through modulating nitric oxide (NO), a well-established mediator of blood pressure and vascular health. RTN-001 is the first therapeutic candidate PDE5 inhibitor designed to preferentially distribute to the aorta and higher vasculature and has been shown in both preclinical and clinical settings to exert a meaningful antihypertensive effect.
RTN-001 has been studied in nine Phase 1 and Phase 2 clinical trials encompassing 265 subjects. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.
Clinical Trials
Planned Phase 2 Study: Retension Pharmaceuticals is planning a multi-center, double-blind, placebo-controlled Phase 2 trial in patients with uncontrolled hypertension who are on 2+ hypertensive medications. The study will further evaluate the effect of RTN-001 on blood pressure, confirm RTN-001’s pharmacokinetic and pharmacodynamic (PK/PD) profile, and expand on the safety profile of RTN-001.
